💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Hester Biosciences Limited is an India-based animal healthcare company. The Company is principally engaged in manufacturing poultry vaccines, large animal vaccines, and trading poultry, large animal, and petcare health products. It operates through three segments: Poultry…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A decent, fast-growing business, trading cheap versus its own history.
Hester Biosciences is scored on the pharma / healthcare framework. It keeps a healthy 16.8% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 1.12× reported profit. Free cash flow is worth about 3.1% of its market value.
Over the last 3 years revenue compounded at 7%/yr and profit at 27%/yr. Book value has grown 8%/yr. Return on equity is a healthy 12.5%. In the latest quarter profit grew 484% versus the prior quarter.
At 35× earnings, the stock sits at the 14th percentile of its own 3.6-year range — the cheap end of where it has historically traded. Today's price implies ~4%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 13.97 | — | — |
| P/B | 4.28 | 4.1 | worse |
| EV/EBITDA | 10.95 | 19.33 | better |
| ROE | 12.53 | — | — |
| ROCE | 14.58 | 14.41 | better |
| ROA | 20.96 | — | — |
| Quick Ratio | 0.89 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
7% CAGR — growing but slowly. Growth is accelerating — latest year outpaced the prior year's rate.
Profit is growing faster than revenue (27% vs 7%) — margin expansion is at work. The latest year saw a +99% swing — check if it's a one-off or structural.
Operating margin has expanded from 14% to 22% — the business is keeping more of each rupee earned.
ROE at 16% — a respectable return on shareholder capital. Capital efficiency improving — ROE up 6pp across the window.
EPS outpaced profit growth — possible buybacks are concentrating earnings into fewer shares. 29% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue fell 19% QoQ — could be seasonality or a genuine slowdown. Run-rate stepping up — recent quarters average 11% above earlier ones.
Profit jumped 484% QoQ — check if this is operating leverage or a one-off item. Quarterly net margins are expanding (18% → 123%) — profitability per rupee of revenue is improving.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters at 44.3% — dispersed ownership; institutional flows drive the stock. Promoters reduced 9.4pp over 4 quarters — watch whether this is planned divestment or pledge invocations.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.